Nazaret Gamez Ruiz, United States of America
The University of Texas Health Science Center at Houston NeurologyAuthor Of 2 Presentations
COGNITIVE IMPAIRMENT AMELIORATION ATTRIBUTED TO INTRAVASCULAR DELIVERY OF NEURAL PRECURSORS IN MOUSE MODELS OF ALZHEIMER’S DISEASE
Abstract
Aims
Alzheimer’s disease is considered a serious global health problem with the increase of the elderly population and the absence of disease-modifying treatments. AD is neuropathologically characterized by the accumulation of β-amyloid in senile plaques and hyper-phosphorylated tau as neurofibrillary tangles, synaptic loss and neuroinflammation. Recently, stem cell therapy has provided great potential treating AD patients. However, there is an urgent need to replace the conventional intracerebral inoculation for a less invasive method to avoid some of the technical challenges but ensuring cells reach the brain. Our recently published results indicated that peripheral treatment with neural precursors (NPs) ameliorates clinical symptoms by reducing the disease-associated neuroinflammation in a mouse model of Parkinson’s disease. Therefore, we hypothesize that intravenous administration of NPs and their released neurotrophic factors can be used as a non-invasive therapy to ameliorate memory impairment in mouse models of AD.
Methods
In this pre-clinical study, NPs derived from mesenchymal stem cells (MSC-NPs) and induced pluripotent stem cells (iPSC-NPs) were intravenously injected into APP/PS1 and P301S mice at 3 or 6 months of age. Before treatment and at the age of 7 months old, experimental and control (PBS) animals were subjected to Barnes maze task and rotarod test.
Results
NPs treated mice displayed an amelioration in memory dysfunction compare to the PBS-injected animals. In addition, P301S mice injected with NPs showed improved motor function to rotarod coordination in comparison to the control group.
Conclusions
Peripheral inoculation using NPs could be used as a treatment to reduce AD-related clinical signs.
LIVE DISCUSSION
- A. Claudio Cuello, Canada
- Nazaret Gamez Ruiz, United States of America
- Kjell A. Svensson, United States of America
- Florin Despa, United States of America
- Roberta D. Brinton, United States of America
- Tangui Maurice, France
- Esther Rawner, United States of America
- Ann M. Gooch, United States of America
Presenter of 2 Presentations
LIVE DISCUSSION
- A. Claudio Cuello, Canada
- Nazaret Gamez Ruiz, United States of America
- Kjell A. Svensson, United States of America
- Florin Despa, United States of America
- Roberta D. Brinton, United States of America
- Tangui Maurice, France
- Esther Rawner, United States of America
- Ann M. Gooch, United States of America
COGNITIVE IMPAIRMENT AMELIORATION ATTRIBUTED TO INTRAVASCULAR DELIVERY OF NEURAL PRECURSORS IN MOUSE MODELS OF ALZHEIMER’S DISEASE
Abstract
Aims
Alzheimer’s disease is considered a serious global health problem with the increase of the elderly population and the absence of disease-modifying treatments. AD is neuropathologically characterized by the accumulation of β-amyloid in senile plaques and hyper-phosphorylated tau as neurofibrillary tangles, synaptic loss and neuroinflammation. Recently, stem cell therapy has provided great potential treating AD patients. However, there is an urgent need to replace the conventional intracerebral inoculation for a less invasive method to avoid some of the technical challenges but ensuring cells reach the brain. Our recently published results indicated that peripheral treatment with neural precursors (NPs) ameliorates clinical symptoms by reducing the disease-associated neuroinflammation in a mouse model of Parkinson’s disease. Therefore, we hypothesize that intravenous administration of NPs and their released neurotrophic factors can be used as a non-invasive therapy to ameliorate memory impairment in mouse models of AD.
Methods
In this pre-clinical study, NPs derived from mesenchymal stem cells (MSC-NPs) and induced pluripotent stem cells (iPSC-NPs) were intravenously injected into APP/PS1 and P301S mice at 3 or 6 months of age. Before treatment and at the age of 7 months old, experimental and control (PBS) animals were subjected to Barnes maze task and rotarod test.
Results
NPs treated mice displayed an amelioration in memory dysfunction compare to the PBS-injected animals. In addition, P301S mice injected with NPs showed improved motor function to rotarod coordination in comparison to the control group.
Conclusions
Peripheral inoculation using NPs could be used as a treatment to reduce AD-related clinical signs.